Inhibition of the growth of human melanoma xenografts in nude mice by human tumor-specific cytotoxic T-cells
- 1 February 1990
- journal article
- research article
- Published by Wiley in Journal of Surgical Oncology
- Vol. 43 (2) , 67-72
- https://doi.org/10.1002/jso.2930430202
Abstract
Melanoma-specific T-cells (CTLs) are specifically cytotoxic for autologous tumor, when assayed in vitro. To examine their effectiveness in vivo, we tested the ability of these human T-cells to inhibit growth of human melanoma xenografts by using a Winn assay. Nude mice receiving specific CTLs (n = 10) demonstrated a dramatic inhibition of tumor growth. All treated mice were tumor-free at day 50 and nine remained tumor-free at day 65, vs. control mice (n= 10) with average tumor volumes of 321 mm3 and 808 mm3, respectively. To control for the possibility that a non-specific response to the human T-cells could inhibit tumor growth, an additional group received allospecific CTLs. There was no inhibition of tumor growth in this group (n =8), with the average tumor volume of 2,768 mm3 at day 40 vs. 1,882 mm3 in the control group (n = 10). We conclude that these tumor-specific CTLs can inhibit tumor growth in vivo and may prove useful in the adoptive immunotherapy of melanoma.Keywords
This publication has 15 references indexed in Scilit:
- Melanoma-Specific Cytotoxic T Cells Generated from Peripheral Blood LymphocytesAnnals of Surgery, 1989
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- Human Cytotoxic T Cells Specific for Autologous Melanoma Cells: Successful Generation From Lymph Node Cells in Seven Consecutive CasesJNCI Journal of the National Cancer Institute, 1988
- Autologous lymph node cell-derived tumor-specific cytotoxic t-cells for use in adoptive immunotherapy of human melanomaCancer, 1988
- Human T Cells Specifically Activated Against Autologous Malignant MelanomaArchives of Surgery, 1987
- A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 AloneNew England Journal of Medicine, 1987
- Constant-Infusion Recombinant Interleukin-2 in Adoptive Immunotherapy of Advanced CancerNew England Journal of Medicine, 1987
- A New Approach to the Adoptive Immunotherapy of Cancer with Tumor-Infiltrating LymphocytesScience, 1986
- Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.The Journal of Experimental Medicine, 1984
- Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.The Journal of Experimental Medicine, 1982